MGC Pharmaceuticals Ltd.
PDMR Notifications
07 April 2022
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company'), a European based bio-pharma company specialising in the production and development of phytomedicines, wishes to advise that the following Person Discharging Managerial Responsibilities (PDMR) has been issued shares in MGC Pharma as a result of exercising Performance Rights granted under the Company's Employee Incentive Plan (Incentive Plan), details of which were announced to the market on 25 February 2021 as part of the Notice of Meeting for the Shareholder Meeting held on 31 March 2021, at which the Incentive Plan was approved.
| 1 | Details of the person discharging managerial responsibilities/person closely associated
| ||||
| (a) | Name | Nicole Godresse | |||
| 2 | Reason for the notification
| ||||
| (a) | Position
| Global Chief Sales Officer | |||
| (b) | Initial notification/amendment
| Initial | |||
| (c) | If amendment: reason
| n/a | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| | Full name of entity | MGC Pharmaceuticals Limited
| |||
| | Legal Entity Identifier Code | 213800HRE3FQJ6RK4H10
| |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
| ||||
| (a) | Description of the financial instrument, type of instrument | Fully Paid Ordinary Shares | |||
| (b) | Identification Code (ISIN)
| AU000000MXC6 | |||
| (c) | Nature of transaction | Issued of shares on the exercise of Performance Rights issued under an Employee Share Plan | |||
| (d) | Currency | Price | Volume | Total | |
| | AUD | $0.024 | 600,000 | 14,400 | |
| | Aggregated information | ||||
| | AUD | $0.024 | 600,000 | 14,400 | |
| (e) | Date of transaction
| 2022-04-07 | |||
| (f) | Place of transaction
| Outside a trading venue | |||
The above transaction forms part of the notification (ASX appendix 2A) to the Australian Securities Exchange (ASX) today whereby the Company requested quotation of 900,000 new MGC Pharma shares on the ASX. A copy of the document lodged with the ASX can be found at the following URL:
https://www.asx.com.au/asxpdf/20220407/pdf/457tgjn24lwm9n.pdf
--Ends--
Authorised for release by the Company Secretary, for further information please contact:
| MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director +61 8 6382 3390 | MGC Pharmaceuticals Ltd David Lim Company Secretary +61 8 6382 3390 |
| UK Broker - Turner Pope Andy Thacker +44 203 657 0050 | UK PR Advisors - Tavistock Charles Vivian / Tim Pearson +44 207 920 3150
|
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline.
Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.
MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.
MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.
Follow us through our social media channels:
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
